• Profile
Close

Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus

Lupus Oct 11, 2019

Benitez A, Torralba K, Ngo M, et al. - Peripheral blood mononuclear cells were isolated from healthy donors and individuals with SLE on Belimumab or standard-of-care therapy (SCT) in order to assess the impacts of the B-cell activating factor (BAFF)-targeting antibody Belimumab on human nonmemory B-cell pools. In comparison with healthy donors and SCT individuals, patients who were treated with Belimumab exhibited modifications in the nonmemory B-cell pool identified by a reduction in the Transitional 2 (T2) subset, and a rise in the proportion of Transitional 1 (T1) cells. No important variations between the groups was demonstrated by the naïve B-cell compartment. Therefore, it was manifested using a translational strategy that Belimumab-mediated BAFF depletion decreases the T2 subset in individuals, comparable to what is noted in mouse models with BAFF depletion.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay